- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.08. | BioAtla stock downgraded by Citizens JMP on cash concerns | 2 | Investing.com | ||
| 08.08. | BioAtla im August 2025: Vielversprechende klinische Daten treffen auf finanziellen Gegenwind | 4 | Investing.com Deutsch | ||
| 08.08. | BioAtla August 2025 slides: promising clinical data amid financial headwinds | 2 | Investing.com | ||
| 07.08. | BioAtla GAAP EPS of -$0.32 misses by $0.03 | 2 | Seeking Alpha | ||
| 07.08. | BioAtla, Inc. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 07.08. | BioAtla, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 04.08. | BioAtla, Inc.: BioAtla to Announce Second Quarter 2025 Financial Results and Provide Business Highlights on August 7, 2025 | 2 | GlobeNewswire (USA) | ||
| BIOATLA Aktie jetzt für 0€ handeln | |||||
| 03.07. | BioAtla, Inc.: BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European ... | 169 | GlobeNewswire (Europe) | Adverse events were generally low-grade, transient, and readily manageable Achieved preliminary evidence of prolonged tumor control and tumor reductions in heavily pretreated adenocarcinoma patients... ► Artikel lesen | |
| 20.06. | BioAtla, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 02.06. | BioAtla reports promising trial results for cancer drug | 4 | Investing.com | ||
| 16.05. | BioAtla, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.05. | BioAtla stock holds $1 target, JMP affirms Market Outperform | 2 | Investing.com | ||
| 06.05. | BioAtla files to sell 9.68M shares of common stock for holders | 3 | Seeking Alpha | ||
| 06.05. | BioAtla, Inc. - 10-Q, Quarterly Report | 6 | SEC Filings | ||
| 06.05. | BioAtla, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 05.05. | A Preview Of BioAtla's Earnings | 3 | Benzinga.com | ||
| 24.04. | BioAtla, Inc.: BioAtla Announces Poster Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting | 2 | GlobeNewswire (USA) | ||
| 23.04. | BioAtla, Inc.: BioAtla Announces Upcoming Poster Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting | 2 | GlobeNewswire (USA) | ||
| 21.04. | BioAtla stock holds $1 target, Market Outperform rating | 3 | Investing.com | ||
| 31.03. | BioAtla stock price target cut to $1 by Citizens JMP | 2 | Investing.com |
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 5,702 | -2,70 % | Evotec Aktie: Bringt der "Insiderkauf" die große Kurs-Wende? | Ein großer "Insiderkauf" machte bei der Evotec Aktie in dieser Woche Schlagzeilen. Wer dachte, dass der Aktienkauf des CEO von Evotec im Wert von knapp 0,3 Millionen Euro aber massive Dynamik in die... ► Artikel lesen | |
| BB BIOTECH | 36,250 | -0,28 % | EQS-PVR: BB BIOTECH AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution | EQS Voting Rights Announcement: BB BIOTECH AG
BB BIOTECH AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide... ► Artikel lesen | |
| CUREVAC | 4,592 | 0,00 % | CureVac Aktie: Sondermeldung sorgt für starke Verunsicherung. Das ist der Grund und so müssen Anleger heute handeln! | ||
| MODERNA | 20,490 | -0,12 % | Moderna, Inc.: Moderna Announces Data to be Presented at the 2025 International Congress of Inborn Errors of Metabolism | CAMBRIDGE, MA / ACCESS Newswire / September 2, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that five abstracts on its investigational mRNA therapeutics have been accepted for presentation at... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | - | - | Boehringer Ingelheim Limited: Boehringer Ingelheim and Palatin Technologies to develop potential first-in-class melanocortin receptor targeted treatment for patients with retinal diseases | · Collaboration strengthens Boehringer's pipeline in Eye Health.· Many patients with diabetic retinopathy (DR) continue to experience vision loss or treatment fatigue, underscoring an... ► Artikel lesen | |
| BIOXXMED | 0,300 | -9,09 % | PTA-Adhoc: bioXXmed AG: Ergebnis für das Geschäftsjahr 2024 - Prognose für das Geschäftsjahr 2025 | DJ PTA-Adhoc: bioXXmed AG: Ergebnis für das Geschäftsjahr 2024 - Prognose für das Geschäftsjahr 2025
Veröffentlichung von Insiderinformationen gemäß Artikel 17 MAR
bioXXmed AG: Ergebnis für... ► Artikel lesen | |
| VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer | SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim Labs"), a pharmaceutical and biotechnology services company that is focused on providing testing... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 2,300 | -0,86 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Second Quarter 2025 Financial Results and Recent Business Highlights | On track to submit Biologics License Application (BLA) for INO-3107 in 2H25, with the goal of file acceptance by year end
Completed design verification (DV) testing... ► Artikel lesen | |
| OCUGEN | 0,880 | -0,74 % | Carisma Therapeutics stock soars after merger agreement with Ocugen | ||
| INFLARX | 1,323 | -10,06 % | H.C. Wainwright assumes coverage on Inflarx stock with Buy rating | ||
| SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem Corp.: Sirona Biochem Update to Shareholders on Financial Status and Operations | VANCOUVER, British Columbia, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) ("Sirona") wishes to provide shareholders with a critical update on the company's financial... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 10,030 | -0,30 % | Cathie Wood's ARK ETF adjusts portfolio, sells Roku stock, buys CRISPR and Intellia | ||
| BIO-GATE | 0,900 | -1,10 % | EQS-DD: Bio-Gate AG: Karl Richter, Zeichnung von Wandelschuldverschreibungen | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
21.08.2025 / 17:58... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,468 | +4,00 % | Defence Therapeutics Inc.: Defence Therapeutics Engages Dr. Amie Phinney as Strategy & Business Advisor to Guide Next Phase of Growth | Montreal, Quebec--(Newsfile Corp. - September 2, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specialized in... ► Artikel lesen | |
| TREVENA | 2,280 | -40,00 % | Hollywood Changemaker Oliver Trevena Joins Little Kitchen Academy as Investor | LOS ANGELES, CA / ACCESS Newswire / August 21, 2025 / Little Kitchen Academy (LKA), the premier Montessori-inspired cooking academy for children and teens ages 3-18, is proud to announce that Oliver... ► Artikel lesen |
BIOATLA INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +2,09 % bei einem Aktienkurs von 0,499 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOATLA INC finden Sie auf Wallstreet Online.